StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report report published on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 target price on the stock in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock opened at $2.37 on Tuesday. Brainstorm Cell Therapeutics has a fifty-two week low of $2.01 and a fifty-two week high of $11.89. The firm has a market capitalization of $166.09 million, a price-to-earnings ratio of -7.44 and a beta of 0.35. The stock’s 50-day simple moving average is $0.40 and its 200-day simple moving average is $0.45.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). During the same quarter in the previous year, the company posted ($0.27) EPS. As a group, equities analysts forecast that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is owned by hedge funds and other institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.